Valneva Stock Forum

$Valneva (VALN.US)$ Valneva Submits Label Extension Application For Its Chikungunya Vaccine, IXCHIQ, To The U.S. FDA To Potentially Include Adolescents And Antibody Persistence Up To 2-Years

$Valneva (VALN.US)$
I notice that when people talk about Valneva, you hear endless talk about Lyme & Chikungunya, but there is almost no talk about SV4, a tetravalent bioconjugate vaccine candidate against shigellosis that is entering Phase 2. It seems that most of the talk regarding this centers around children in third world underdeveloped countries, but there is a possible huge market if it gets worked into the standard childhood vaccine sched...

$Valneva (VALN.US)$ Pfizer, Valneva Report Further Positive Phase 2 Booster Results For Lyme Disease Vaccine Candidate
Drug makers Pfizer Inc. (PFE) and Valneva SE (VALN) announced Tuesday positive immunogenicity and safety data from their VLA15-221 Phase 2 study following a second booster vaccination of their Lyme disease vaccine candidate, VLA15, given one year after receiving the first booster dose.
Pfizer aims to submit a Biologics License Application or BLA to the U.S. Food and Drug Ad...

$Valneva (VALN.US)$ Valneva is set to receive up to $41.3 million from CEPI and the EU to enhance access to IXCHIQ®, the world’s first chikungunya vaccine, particularly in low- and middle-income countries. The funding will bolster clinical trials in vulnerable groups and support technology transfer to additional manufacturers, ensuring wider distribution in regions at risk of chikungunya outbreaks. With approvals already in place in the U.S., Canada, and Europe, the company aims to extend the...

$Valneva (VALN.US)$ Valneva's Chikungunya Vaccine Secures Approval for Use in EU
MT Newswires· 4 mins ago

$Valneva (VALN.US)$ Results Intended to Support Filing for Potential Label Extension for Use in Adolescents Saint-Herblain (France), May 13, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today reported further positive pivotal Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine. Following the initial analysis up to Day 29 post-vaccination, the most recent analysis of study VLA1553-321 evaluated the safety and immunogenicity six months...

$Annovis Bio (ANVS.US)$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...